AbbVie wins FDA approval for Parkinson’s drug
AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.
AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.
Maris-Tech (NASDAQ:MTEK) received a US$10 million order to develop and supply video systems for next-generation manned airborne platforms under a multi-year project with Magam Safety.
TransDigm Group (NYSE:TDG) completed its acquisition of Prince & Izant for approximately $1.066 billion in cash, including certain tax benefits.
Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.
Bitget has resumed Bitcoin (BTC) withdrawals after a security breach affecting nearly $388 million.
Ramaco Resources (NASDAQ:METC) secured a $30 million court judgment for its subsidiary Ramaco Resources in an insurance coverage dispute against Chubb subsidiaries Federal Insurance Company and ACE American Insurance Company.
Palatin Technologies (NASDAQ:PTN) reported fiscal 2026 collaboration and license revenue of $13.2 million, compared with zero revenue in fiscal 2025.
Kandi Technologies (NASDAQ:KNDI) secured a second heavy-truck battery swap station equipment order through its China Battery Exchange subsidiary from QIJI Energy, a subsidiary of CATL.
South Korea’s Financial Services Commission has begun considering market-making rules for digital assets.
AN2 Therapeutics (NASDAQ:ANTX) received an extension of funding from the Gates Foundation to support its tuberculosis research collaboration with GSK focused on boron-based leucyl-tRNA synthetase inhibitors.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade